JP2018514564A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514564A5
JP2018514564A5 JP2017556853A JP2017556853A JP2018514564A5 JP 2018514564 A5 JP2018514564 A5 JP 2018514564A5 JP 2017556853 A JP2017556853 A JP 2017556853A JP 2017556853 A JP2017556853 A JP 2017556853A JP 2018514564 A5 JP2018514564 A5 JP 2018514564A5
Authority
JP
Japan
Prior art keywords
powder
zolmitriptan
particles
powder formulation
phosphatidyl choline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514564A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/030219 external-priority patent/WO2016179026A1/en
Publication of JP2018514564A publication Critical patent/JP2018514564A/ja
Publication of JP2018514564A5 publication Critical patent/JP2018514564A5/ja
Pending legal-status Critical Current

Links

JP2017556853A 2015-05-01 2016-04-29 肺送達用のゾルミトリプタン粉末 Pending JP2018514564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155910P 2015-05-01 2015-05-01
US62/155,910 2015-05-01
PCT/US2016/030219 WO2016179026A1 (en) 2015-05-01 2016-04-29 Zolmitriptan powders for pulmonary delivery

Publications (2)

Publication Number Publication Date
JP2018514564A JP2018514564A (ja) 2018-06-07
JP2018514564A5 true JP2018514564A5 (OSRAM) 2019-06-06

Family

ID=56027187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556853A Pending JP2018514564A (ja) 2015-05-01 2016-04-29 肺送達用のゾルミトリプタン粉末

Country Status (9)

Country Link
US (1) US20160317503A1 (OSRAM)
EP (1) EP3288591A1 (OSRAM)
JP (1) JP2018514564A (OSRAM)
KR (1) KR20180002750A (OSRAM)
AU (1) AU2016257729A1 (OSRAM)
CA (1) CA2984339A1 (OSRAM)
HK (1) HK1251998A1 (OSRAM)
MX (1) MX2017013950A (OSRAM)
WO (1) WO2016179026A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034857B2 (en) * 2015-07-02 2018-07-31 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
CA3085943A1 (en) * 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
WO2020102394A1 (en) * 2018-11-13 2020-05-22 Civitas Therapeutics, Inc. Respirable polynucleotide powder formulations for inhalation
BR112022023307A2 (pt) 2020-05-18 2022-12-20 Orexo Ab Composição farmacêutica para entrega de fármacos
CA3238850A1 (en) 2021-11-25 2023-06-01 Jonas Savmarker Pharmaceutical composition comprising adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
AU2003230689B2 (en) * 2002-03-20 2006-06-29 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
CA2728808A1 (en) * 2008-02-01 2009-08-06 Vectura Limited Pulmonary formulations of triptans
JP6092113B2 (ja) * 2010-11-09 2017-03-08 マンカインド コーポレイション セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione

Similar Documents

Publication Publication Date Title
JP2018514564A5 (OSRAM)
CN111249260B (zh) 包含rpl554的液体吸入制剂
JP5111517B2 (ja) バルガンシクロビルの粉末製剤
Minne et al. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients
JP6154803B2 (ja) 膣投与のための迅速溶解性錠剤組成物
CN110522744B (zh) 用于改善肺功能和用于预防和/或治疗辐射诱发的肺并发症的材料和方法
ES2525163T3 (es) Método para preparar composiciones farmacéuticas pretendidas para administración oral que comprenden uno o más ingredientes activos y las composiciones que comprenden los mismos
US20190022053A1 (en) Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
US20130098357A1 (en) Cerivastatin to treat pulmonary disorders
DK2698147T3 (en) Oral film formulation with dapoxetine tadalafil
MX2014001345A (es) Metodo y formulacion para inhalacion.
PT1296663E (pt) Administração altamente eficaz de um aerosol de grande massa terapêutica
JP2010503731A (ja) 肺サーファクタント製剤および粘液クリアランスの促進方法
JP2016534153A5 (OSRAM)
JP7680823B2 (ja) 吸入可能なニコチン製剤、およびその作製および使用方法
CN101631563B (zh) 含有流感疫苗的冻干制剂及其制备方法
JP2016532672A5 (OSRAM)
CN109833311B (zh) 一种口溶膜组合物
CN102078312A (zh) 一种姜黄素类化合物干粉吸入剂及其制备方法和用途
JP2023071886A5 (OSRAM)
JP6316422B2 (ja) フィンゴリモドの医薬組成物
JP7654544B2 (ja) ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
JP2019518782A (ja) 吸入用サーファクタント製剤
JPWO2019237028A5 (ja) 吸入のための組成物
WO2022116792A1 (zh) 一种用于治疗肺结核的异烟肼干粉吸入剂